Korea GSK Appoints Maurizio Bogata as New President

GlaxoSmithKline Korea (GSK) announced on the 4th that Maurizio Borgatta has been appointed as the new General Manager, effective from the 1st of this month.

Maurizio Borgatta, New President of Korea GSK
[Photo by Korea GSK]

Since joining GSK in 2015, General Manager Borgatta has been recognized for his business leadership, employee-centered strategies, and achievements across various therapeutic area divisions. He is particularly credited with successfully establishing GSK’s pharmaceuticals and vaccines in European markets such as Belgium, Spain, Italy, and the United Kingdom. Prior to joining GSK, he held multiple roles over nine years in multinational consumer goods companies across Latin America, Europe, and Asia.

From 2021, he served as the President of GSK Portugal, where he successfully expanded eight innovative drug indications and entered two new vaccine markets. Under his leadership, GSK Portugal was also recognized as one of the ‘Best Places to Work,’ reflecting his success in establishing a strong corporate culture.

President Borgatta stated, “I am pleased to join GSK Korea, which has achieved impressive growth in vaccines and specialty medicines, and to work together with the team. I will do my best alongside Korean employees to enhance accessibility to GSK’s broad vaccine portfolio and various innovative therapies, ensure stable supply, stay ahead of diseases, and contribute to improving patients’ quality of life.”

Rob Kempton, who has led GSK Korea since 2020, was recognized for bringing significant changes to the organizational culture and capabilities of GSK Korea and achieving business growth. He has been appointed as Head Vaccines Market Lead, Europe.

This content was produced with the assistance of AI translation services.